Experts present advances in treating neurological disease at the INS 13th World Congress

March 30, 2017

EDINBURGH, Scotland - Experts will present diverse advances in neuromodulation from May 27 to June 1, 2017 at the 13th World Congress of the International Neuromodulation Society (INS) in Edinburgh, Scotland. The INS congress will draw more than 1,400 scientists, clinicians and engineers to the Edinburgh International Conference Centre.

Since the first report of spinal cord stimulation for chronic pain 50 years ago, neurostimulation has become one of the fastest-growing fields in medicine.

"The overall event signifies the explosion in knowledge that brings specialists of diverse disciplines to the congress," noted INS President Timothy Deer, M.D. "We are looking forward to welcoming delegates to Edinburgh, a World Heritage site and center of neuroscience breakthroughs.

"The congress theme, 'Neuromodulation: Technology Changing Lives,' underscores how neuromodulation relieves suffering, improves functioning, and increases quality of life. Importantly, neurostimulation offers a non-drug alternative to painkillers for chronic pain."

For the first time, the congress will offer a preconference that focuses solely on noninvasive brain stimulation (NIBS). The May 27 NIBS preconference includes a special abstract competition.

The next day, May 28, the INS offers its popular Innovations Day preconference. The daylong event brings together more than 200 innovators, entrepreneurs, and venture capitalists to network, see emerging company presentations, and learn from expert panelists about commercialization pathways. Several previous early stage company presenters have entered the commercial marketplace since the first Innovations Day in 2011.

The 3.5-day scientific program from May 29 to June 1 includes plenary lectures and parallel-track sessions.

An opening-day plenary session will highlight the latest neuromodulation guidelines about safe, appropriate use of implanted neuromodulation therapies. The guidance by the Neurostimulation Appropriateness Consensus Committee and Polyanalgesic Consensus Conference appeared in the INS journal, Neuromodulation: Technology at the Neural Interface, in January and February 2017.

At a general assembly of members May 31, colleagues will honor pain physician Michael Stanton-Hicks, M.D. as a Giant of Neuromodulation. His contributions helped catalyze a modern understanding of one of the best indications for neurostimulation, the rare, challenging condition complex regional pain syndrome.

A special program of particular interest to local researchers and physicians the afternoon of May 31 will feature "Pain Research & Neuromodulation in Scotland", organized by the local INS chapter, the Neuromodulation Society of the United Kingdom and Ireland.

Topics to be covered during the INS 13th World Congress 3.5-day scientific program include:
To learn more, see:

About the International Neuromodulation Society

The nonprofit International Neuromodulation Society presents up-to-date information about the full breadth of neuromodulation therapies through an interactive website, its journal Neuromodulation: Technology at the Neural Interface, annual regional meetings, and its biennial world congress.

About Neuromodulation

Neuromodulation therapy, sometimes referred to as bioelectric medicine or electroceuticals, is one of medicine's fastest-growing fields, driven by rising neurological disease in an aging population, and the need for non-pharmacological approaches to manage symptoms. The first use of spinal cord stimulation (SCS) to treat chronic pain of neuropathic origin was reported in 1967 by C. Norman Shealy, M.D., Ph.D. Neuromodulation devices, such as SCS and deep brain stimulation systems, leverage technology developed for cardiac pacemakers and cochlear implants to re-balance neural activity. Neuromodulation therapies help relieve chronic pain or restore function. Existing and emerging devices operate through targeted application of electrical, magnetic, chemical, or optical stimulation. Current or emerging neuromodulation therapies address deficits in vision, hearing, breathing, mobility, grasp or gait, motor function, mood, memory, and digestion.

International Neuromodulation Society

Related Chronic Pain Articles from Brightsurf:

Researchers are developing potential treatment for chronic pain
Researchers from the University of Copenhagen have developed a new way to treat chronic pain which has been tested in mice.

Molecular link between chronic pain and depression revealed
Researchers at Hokkaido University have identified the brain mechanism linking chronic pain and depression in rats.

How chikungunya virus may cause chronic joint pain
A new method for permanently marking cells infected with chikungunya virus could reveal how the virus continues to cause joint pain for months to years after the initial infection, according to a study published Aug.

Gastroesophageal reflux associated with chronic pain in temporomandibular joint
Gastroesophageal reflux (GERD) is associated with chronic, painful temporomandibular disorder -- pain in the temporomandibular joint -- and anxiety and poor sleep contribute to this association, according to a study in CMAJ.

One step closer to chronic pain relief
While effective drugs against chronic pain are not just around the corner, researchers from Aarhus University, Denmark, have succeeded in identifying a protein as a future potential target for medicinal drugs.

Gut bacteria associated with chronic pain for first time
In a paper published today in the journal Pain, a Montreal-based research team has shown, for the first time, that there are alterations in the bacteria in the gastrointestinal tracts of people with fibromyalgia.

Nearly 5.4 million cancer survivors suffer chronic pain
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

New target for chronic pain relief confirmed by scientists
A research group at Hiroshima University observed a potential new target for chronic pain treatment.

Menopause symptoms nearly double the risk of chronic pain
In addition to the other health conditions affected by estrogen, it has also been shown to affect pain sensitivity.

Read More: Chronic Pain News and Chronic Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to